Bayer AG plans to recall the remaining supplies of its drug Trasylol for blood clotting from the U.S. market according to the Food and Drug Administration.
The agency said on Wednesday that access to the product will be limited to investigational use.
The drug, used in heart surgery was suspended for sale on November 2007 after a Canadian clinical study showed it increased risk for death compared to two other drugs used to control bleeding during surgery, according to the FDA.
Trasylol is allowed in a protocol for certain patients who are at high risk of blood loss and transfusions during coronary artery bypass surgery and don't have an alternative therapy.
Shares of Bayer were lastly trading at $56 euros or 0.69 percent down on Frankfurt.